254 related articles for article (PubMed ID: 26931080)
21. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
22. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
23. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
24. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
25. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
26. Forecast: rough seas for leukemia.
Hockenbery DM
Cancer Discov; 2014 Mar; 4(3):278-9. PubMed ID: 24596202
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis therapy: driving cancers down the road to ruin.
Green DR; Walczak H
Nat Med; 2013 Feb; 19(2):131-3. PubMed ID: 23389605
[No Abstract] [Full Text] [Related]
28. Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
[TBL] [Abstract][Full Text] [Related]
29. Targeting apoptotic pathways to treat lymphoid malignancies.
Roberts AW
Rinsho Ketsueki; 2016; 57(10):2054-2058. PubMed ID: 27795514
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
31. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
32. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):18-9. PubMed ID: 25768998
[No Abstract] [Full Text] [Related]
33. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
34. Targeting Bcl-2 Family Proteins: What, Where, When?
Senichkin VV; Pervushin NV; Zuev AP; Zhivotovsky B; Kopeina GS
Biochemistry (Mosc); 2020 Oct; 85(10):1210-1226. PubMed ID: 33202206
[TBL] [Abstract][Full Text] [Related]
35. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
[No Abstract] [Full Text] [Related]
36. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.
Pronier E; Levine RL
Cancer Cell; 2015 Mar; 27(3):323-5. PubMed ID: 25759018
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.
Li X; Dou J; You Q; Jiang Z
Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128
[TBL] [Abstract][Full Text] [Related]
38. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
Dousset C; Maïga S; Gomez-Bougie P; Le Coq J; Touzeau C; Moreau P; Le Gouill S; Chiron D; Pellat-Deceunynck C; Moreau-Aubry A; Amiot M
Br J Haematol; 2017 Nov; 179(4):684-688. PubMed ID: 27471002
[No Abstract] [Full Text] [Related]
39. A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.
Verma A; Steidl U
Nat Med; 2015 Feb; 21(2):113-4. PubMed ID: 25654599
[No Abstract] [Full Text] [Related]
40. Venetoclax: First Global Approval.
Deeks ED
Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]